Dynamics of NITs (LIVERFASt, FIB-4, VCTE) during monitoring therapy with Resmetirom in patients with MASH — update easlfibronostg on June 29, 2026 Category: Publication Highlights, Publications Tag: Clinical Pathway, LIVERFASt, MASH, Monitoring, Resmetirom Post navigation Previous: Previous post: Noninvasive initiation and monitoring of Resmetirom therapy using LIVERFASt, FIB-4 and VCTE in patients with MASHNext: Next post: LIVERFASt outperforms FIB-4, in sequential combination with VCTE, for identifying ≥F3 stages in MASLD including T2DM
